Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Some index funds distribute fewer capital gains than others, which can reduce tax surprises and improve after-tax performance over time.
28,126 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
A Kuwaiti air base attack injures Americans while Washington wavers on a potential Iran ceasefire extension. The unfo...
Two bold moves by Eli Lilly are reshaping the billion-dollar obesity drug market. This guide breaks down what happene...
A federal trade court has struck down a second round of tariffs ordered during the Trump administration. The decision...
Applied Optoelectronics has rocketed higher in 2026, delivering a 439% year-to-date gain as hyperscale AI data center...
FIFA President Gianni Infantino defended Mexico’s readiness as violence roils the country near the World Cup. This pi...
Barclays slashed Coinbase’s price target to $107 following aQ1 2026 revenue miss, highlighting a tug-of-war between c...
XRP sentiment has slid to multi-month lows as traders await catalysts, but analysts warn that the worst periods can p...
Peter Thiel warns that AI may imperil technical roles more than creative ones, a shift that could reshape wages and p...
The Trade Desk has faced a tough stretch, but patient investors are asking if the trade desk stock finally offers a p...
A high-profile inmate known as the Gilgo Beach serial killer is spending years in isolation, reading crime fiction, a...
VOdds rolls out Odds Scanner, a live odds comparison tool designed for crypto bettors. The platform aggregates prices...